Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Xpeng Inc - ADR (XPEV) Price & Performance

Cassava Sciences IncTrade
Xpeng Inc - ADRTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Xpeng Inc - ADR — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Xpeng Inc - ADR trades at $11.76 (market cap $11.15B). The key difference: Xpeng Inc - ADR is far larger — about 233.5× Cassava Sciences Inc's market cap. Which is the better fit depends on your goals.

FLNAXPEV
Market Cap
$47.75M$11.15B
Sector
HealthConsumer Cyclical
52-Week High
$4.64$28.07
52-Week Low
$0.87$11.68
Enterprise Value
-$34.93M$13.28B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.9528, down 4.46% today, with a bearish technical outlook but strong analyst support (66.7% buy ratings). The company continues to post net losses and negative cash flows, though recent EPS beats show some operational improvement. Recent news highlights Q2 2026 results and business updates on Tuberous Sclerosis Complex therapies.

The outlook remains speculative due to persistent unprofitability and cash burn, but analyst optimism and a low P/B ratio of 0.75 may attract value investors. Key risks include execution challenges in drug development and reliance on financing amid negative earnings.

Xpeng Inc - ADR

XPeng (XPEV) trades at $11.76, down 2.04% today, amid a bearish technical signal. The company reported a net loss of $1.14 billion in 2025 despite revenue growth to $76.72 billion, with profitability metrics like ROE at -7.64% remaining weak. Recent news highlights expansion into robotics and overseas markets, including a new SUV launch in Munich, while July 2026 deliveries increased 4% year-over-year to 38,027 vehicles.

The stock offers potential upside to the $17.00 analyst consensus target but faces risks from persistent losses, intense EV competition, and macroeconomic pressures. Investor sentiment is mixed, with 64.7% of analysts rating it a buy, but technical indicators suggest near-term caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Xpeng Inc - ADR

Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.

Read more on XPEV